Orally-bioavailable nucleoside analogs
US11638715B2 · kind B2 · utility
5Cited by
0References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 16, 2022 |
| Grant date | May 2, 2023 |
| Priority date | — |
| Expiry date | Jun 16, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.